Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

Gad Singer, Robert Oldt, Yoram Cohen, Brant G. Wang, David Sidransky, Robert J Kurman, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) invasive micropapillary serous carcinomas (MPSCs; low-grade tumors) and in 31 of 51 (61%) serous borderline tumors (precursor lesions to invasive MPSCs). None of the tumors contained a mutation in both BRAF and KRAS. In contrast, none of the 72 conventional aggressive high-grade serous carcinomas analyzed contained the BRAF codon 599 mutation or either of the two KRAS mutations. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.

Original languageEnglish (US)
Pages (from-to)484-486
Number of pages3
JournalJournal of the National Cancer Institute
Volume95
Issue number6
StatePublished - Mar 19 2003

Fingerprint

Carcinoma
Mutation
Codon
Neoplasms
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. / Singer, Gad; Oldt, Robert; Cohen, Yoram; Wang, Brant G.; Sidransky, David; Kurman, Robert J; Shih, Ie Ming.

In: Journal of the National Cancer Institute, Vol. 95, No. 6, 19.03.2003, p. 484-486.

Research output: Contribution to journalArticle

@article{c230a77d91a4482b8f82167117fdbca0,
title = "Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma",
abstract = "Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68{\%}) invasive micropapillary serous carcinomas (MPSCs; low-grade tumors) and in 31 of 51 (61{\%}) serous borderline tumors (precursor lesions to invasive MPSCs). None of the tumors contained a mutation in both BRAF and KRAS. In contrast, none of the 72 conventional aggressive high-grade serous carcinomas analyzed contained the BRAF codon 599 mutation or either of the two KRAS mutations. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.",
author = "Gad Singer and Robert Oldt and Yoram Cohen and Wang, {Brant G.} and David Sidransky and Kurman, {Robert J} and Shih, {Ie Ming}",
year = "2003",
month = "3",
day = "19",
language = "English (US)",
volume = "95",
pages = "484--486",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

AU - Singer, Gad

AU - Oldt, Robert

AU - Cohen, Yoram

AU - Wang, Brant G.

AU - Sidransky, David

AU - Kurman, Robert J

AU - Shih, Ie Ming

PY - 2003/3/19

Y1 - 2003/3/19

N2 - Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) invasive micropapillary serous carcinomas (MPSCs; low-grade tumors) and in 31 of 51 (61%) serous borderline tumors (precursor lesions to invasive MPSCs). None of the tumors contained a mutation in both BRAF and KRAS. In contrast, none of the 72 conventional aggressive high-grade serous carcinomas analyzed contained the BRAF codon 599 mutation or either of the two KRAS mutations. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.

AB - Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a variety of human cancers. To determine the role of mutations in BRAF and KRAS in ovarian carcinoma, we analyzed both genes for three common mutations (at codon 599 of BRAF and codons 12 and 13 of KRAS). Mutations in either codon 599 of BRAF or codons 12 and 13 of KRAS occurred in 15 of 22 (68%) invasive micropapillary serous carcinomas (MPSCs; low-grade tumors) and in 31 of 51 (61%) serous borderline tumors (precursor lesions to invasive MPSCs). None of the tumors contained a mutation in both BRAF and KRAS. In contrast, none of the 72 conventional aggressive high-grade serous carcinomas analyzed contained the BRAF codon 599 mutation or either of the two KRAS mutations. The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.

UR - http://www.scopus.com/inward/record.url?scp=0037454224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037454224&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 484

EP - 486

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -